



Fax: 866-336-9530  
Toll Free: 1-866-DEO-9530  
E-mail: [investorinfo@deobiosciences.com](mailto:investorinfo@deobiosciences.com)  
[www.deobiosciences.com](http://www.deobiosciences.com)

*John F. Adamson, Jr.*  
*President & CEO*

March 8, 2022

Dear Investors and Followers:

We previously explained in our offering page that we would add expertise to our operations and advisory board, as appropriate, for that particular phase of development. Well, we're happy to announce the addition of an advisory board member as we prepare to enter the next phase of our research and development journey.

**New Advisory Board Member:**

We gratefully welcome Dr. Wayne D. Bowen, Upjohn Professor of Pharmacology, and Chairman of the Department of Molecular Pharmacology, Physiology & Biotechnology in the Division of Biology and Medicine at Brown University in Providence, Rhode Island, as an advisor.

Dr. Bowen is a nationally recognized leader in research on sigma receptors, membrane proteins found in tissues throughout the body that are highly upregulated in cancer cells. He has shown that activation of sigma-2 receptors induces apoptotic cell death, and therefore they may serve as regulators of cell proliferation and survival. He is interested in signal transduction, particularly those pathways that lead to receptor-mediated cell death. Trained initially as a chemist, he maintains a strong interest and involvement in medicinal chemistry and drug design, particularly in relation to development of selective sigma receptor agonists and antagonists. He is exploring these compounds as potential anti-neoplastic, tumor diagnostic, and neuroprotective agents.

Dr. Bowen currently co-directs the medical school's pharmacology course, teaches in endocrinology and neuroscience courses for undergraduates, and co-directs the core pharmacology course for the Molecular Pharmacology and Physiology Graduate Program. Dr. Bowen is a member of the Society for Neuroscience, the International Brain Research Organization/World Federation of Neuroscientists, and the American Association for Cancer Research. He is the recipient of numerous awards and honors, and has performed service on NIMH and NIDA Study Sections. Prior to joining Brown University in his current capacity, Dr. Bowen established the Unit on Receptor Biochemistry and Pharmacology within the Laboratory of Medicinal Chemistry of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH).

Dr. Wayne Bowen earned his B.S. in chemistry from Morgan State College and completed his Ph.D. in biochemistry and neurobiology at Cornell University. He conducted postdoctoral studies at the National Institute of Mental Health (NIMH) in the NIH.

Dr. Bowen's institutional pedigree is impeccable and his research record comports with our goals for expanding our field of knowledge in apoptosis in cancer medicine. We're excited to have access to his intellect and unique expertise as we pursue further testing, evaluation, and development of our discoveries and research thesis. Again, we enthusiastically welcome Dr. Bowen to the DeoBioSciences family and commercialization journey.

We expect to periodically enhance our board of advisors and community of expertise, as appropriate, and consistent with our developmental progress. This appointment is indicative of that.

Thank you for continuing to be a visionary and fearless ground-floor partner in our journey! More to come before our campaign end. Until then, be well.

A handwritten signature in black ink, appearing to be 'John A.', written in a cursive style.

John A. & Team DeoBioSciences